Eli Lilly and Company (NYSE: LLY) announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening ...
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (d...
TrakCel, a provider of integrated cell and gene therapy (CGT) orchestration solutions for the precise management, control and tracking of CGTs has announce...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focus...
ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, announced that it has received a P...
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced that the United States (U.S.) Food and D...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the pivotal Phase 3 study design following successful alignment with the U.S. Food and...
The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifical...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New ...
QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that a detailed analysis of the positive Phase III INAVO120 results, evaluat...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced new late-breaking data on its Elecsys Amyloid Plasma Panel (combination of pTau181 and ApoE4), for Alzhei...
Eli Lilly and Company (NYSE: LLY) announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related imaging...
© 2024 Biopharma Boardroom. All Rights Reserved.
